This company has been marked as potentially delisted and may not be actively trading. TenX Keane Acquisition (TENK) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsOwnershipTrendsBuy This Stock TENK vs. ATNM, ESLA, RNXT, FGEN, PDSB, AADI, DYAI, OTLK, ZIVO, and NBRVShould you be buying TenX Keane Acquisition stock or one of its competitors? The main competitors of TenX Keane Acquisition include Actinium Pharmaceuticals (ATNM), Estrella Immunopharma (ESLA), RenovoRx (RNXT), FibroGen (FGEN), PDS Biotechnology (PDSB), Aadi Bioscience (AADI), Dyadic International (DYAI), Oncobiologics (OTLK), ZIVO Bioscience (ZIVO), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry. TenX Keane Acquisition vs. Its Competitors Actinium Pharmaceuticals Estrella Immunopharma RenovoRx FibroGen PDS Biotechnology Aadi Bioscience Dyadic International Oncobiologics ZIVO Bioscience Nabriva Therapeutics TenX Keane Acquisition (NASDAQ:TENK) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation. Do institutionals and insiders believe in TENK or ATNM? 70.5% of TenX Keane Acquisition shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 22.9% of TenX Keane Acquisition shares are owned by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer TENK or ATNM? In the previous week, TenX Keane Acquisition's average media sentiment score of 0.00 equaled Actinium Pharmaceuticals'average media sentiment score. Company Overall Sentiment TenX Keane Acquisition Neutral Actinium Pharmaceuticals Neutral Do analysts recommend TENK or ATNM? Actinium Pharmaceuticals has a consensus target price of $4.50, indicating a potential upside of 200.00%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than TenX Keane Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TenX Keane Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TENK or ATNM more profitable? TenX Keane Acquisition's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets TenX Keane AcquisitionN/A N/A N/A Actinium Pharmaceuticals N/A -100.85%-47.89% Which has preferable earnings & valuation, TENK or ATNM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenX Keane AcquisitionN/AN/AN/AN/AN/AActinium PharmaceuticalsN/AN/A-$48.82M-$1.31-1.15 SummaryTenX Keane Acquisition beats Actinium Pharmaceuticals on 4 of the 7 factors compared between the two stocks. Get TenX Keane Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TENK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENK vs. The Competition Export to ExcelMetricTenX Keane AcquisitionHolding Offices Industry SectorNASDAQ ExchangeMarket Cap$12.18M$236.69M$2.48B$10.64BDividend YieldN/A3.13%13.80%4.69%P/E RatioN/A0.1727.8427.64Price / SalesN/A456.098,381.13205.24Price / CashN/A123.7060.0662.20Price / BookN/A7.353.386.79Net IncomeN/A-$12.18M-$445.27M$275.88M TenX Keane Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENKTenX Keane AcquisitionN/A$1.83-0.5%N/A+78.6%$12.18MN/A0.00N/AGap UpHigh Trading VolumeATNMActinium Pharmaceuticals1.9109 of 5 stars$1.60flat$4.50+181.3%-4.2%$49.91MN/A-1.1530ESLAEstrella Immunopharma2.4513 of 5 stars$1.32-1.5%$16.00+1,112.1%+36.3%$49.67MN/A-5.08N/ANews CoverageAnalyst ForecastRNXTRenovoRx2.2039 of 5 stars$1.27-5.2%$7.50+490.6%+13.1%$49.11M$662K-3.346News CoverageAnalyst ForecastFGENFibroGen4.3232 of 5 stars$11.93-0.7%$43.00+260.4%+33.8%$48.63M$29.62M-31.39570News CoverageAnalyst ForecastPDSBPDS Biotechnology2.1935 of 5 stars$1.02flat$10.00+880.4%-71.0%$47.97MN/A-1.1120Analyst ForecastAADIAadi BioscienceN/A$1.91+0.5%N/A+7.0%$47.17M$25.07M-0.8440Gap DownDYAIDyadic International3.0774 of 5 stars$1.22-6.2%$6.00+391.8%+0.0%$47.04M$3.42M-6.427Analyst ForecastGap UpOTLKOncobiologics2.6945 of 5 stars$1.07+2.9%$7.00+554.2%-75.2%$46.20MN/A-1.8820News CoverageAnalyst ForecastZIVOZIVO Bioscience0.1088 of 5 stars$12.03-5.6%N/A-34.0%$45.92M$15.85K-2.4710Gap UpHigh Trading VolumeNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies ATNM Alternatives ESLA Alternatives RNXT Alternatives FGEN Alternatives PDSB Alternatives AADI Alternatives DYAI Alternatives OTLK Alternatives ZIVO Alternatives NBRV Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENK) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored"I'm risking my reputation on this"The Fed rate cut truth they don't want you to know The Fed's 25 basis point cut isn't just monetary policy…...Crypto 101 Media | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredElon callingElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TenX Keane Acquisition Please log in to your account or sign up in order to add this asset to your watchlist. Share TenX Keane Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
